Search results for: Health Policy and Regulation
Filter search results
Establishing a Reasonable Price for an Orphan Drug
1 July 2018
…a way to adjust the established cost-effectiveness thresholds (CETs) by several factors, including, the size of patient populations and the costs of research and development (R&D). Once adjusted, CETs sustain…
Securing Funds for the Proposed NHS Multi-year Funding: The Feasibility of Using a Hypothecated Tax
1 October 2018
This OHE publication by Nick Timmins, a senior fellow at the Institute for Government and the Kings Fund, sets out arguments in favour and against. It is based on the…
Multi-Indication Pricing (MIP): Practical Solutions and Steps to Move Forward
1 December 2018
…be set at a cost-effective level for each indication and patient sub-population, thereby expanding treatment to more patients and stimulating future research as manufacturers anticipate a sufficient return on R&D…
Can a Strong Economic Case Be Made for Investing in the NHS?
1 January 2019
…promote the government’s macroeconomic objectives, including sustainable public finances; a stable economy and financial system; and structural reforms to increase employment, productivity, growth, and international competitiveness; and supporting societal wellbeing….
The Future of Global Health Procurement: Issues around Pricing Transparency
1 March 2019
…that price transparency may play in the efficient and effective procurement of medicines by Middle and Low Income Countries. Will making prices publicly available make procurement more efficient and cost-effective…
Indication-Based Pricing (IBP) Discussion Paper: Should drug prices differ by indication?
1 May 2019
Increasingly, scientific advances are delivering new medicines that deliver improved survival and quality of life across multiple treatment indications. Indication-Based Pricing (IBP) has been proposed as a way to better…
Documento de debate sobre la fijación de precios en función de la indicación (IBP) ¿Deben variar los precios de los medicamentos según la indicación?
1 June 2019
Cada vez más, los avances científicos desarrollan nuevas medicinas que permiten mejoras en la supervivencia y calidad de vida para diversas indicaciones terapéuticas. La fijación de precios en función de…
Indication-Based Pricing (IBP) Consultation Report
1 April 2020
…permits price to vary according to indication and has been proposed to tackle this issue. In a previous Discussion Paper we outlined the key potential benefits and drawbacks of IBP,…
Delivering the 2.4 Percent: Unlocking UK Pharma R&D Investment through Evidence-Based Policies
1 June 2020
…Health Economics (OHE) was commissioned to investigate how the UK Government and the UK pharmaceutical industry can collaborate to deliver the life science sector’s share of this ambitious R&D target….